All In Biotech

Drug Trial Radar · NCT05456932

Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease

Last checked: Nov 20, 2026Latest source record: Mar 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

90

Planned (sponsor's estimate)

Start

Aug 19, 2022

Primary completion

Aug 31, 2023

Study completion Aug 31, 2023

Sponsor

Lead sponsor
Leiden University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University Medical Center Groningen; Radboud University Medical Center; Maastricht University Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
First posted
Jul 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Iron deficiency anemia is the most common systemic manifestation of Inflammatory Bowel Diseases (IBD)-Crohn's disease and ulcerative colitis. Iron deficiency with or without anemia poses a diagnostic and therapeutic challenge due to chronic gastrointestinal blood loss and the inflammatory nature of IBD. Recent illumination of iron metabolism has brought attention to the systemic iron regulator-hepcidin, a peptide hormone that regulates intestinal iron absorption and systemic iron availability. Elevated hepcidin is associated with oral iron malabsorption in IBD. This study aims to evaluate whether hepcidin concentration at baseline can predict response to oral and intravenous iron therapy in patients with IBD and concomitant iron deficiency with or without anemia.

Conditions

  • Inflammatory Bowel Diseases
  • Iron-deficiency
  • Iron Deficiency Anemia

Interventions

  • Intravenous ironDrug

    Included participants will receive intravenous iron therapy, the dosage will be based on national pharmaceutical formulary.

  • Ferric maltolDrug

    Included participants will receive oral iron therapy with ferric maltol (twice a day 30mg for 12 weeks)

  • Ferrous fumarateDrug

    Included participants will receive oral iron therapy with ferrous fumarate (twice a day 100mg for 12 weeks)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The discriminative capacity of hepcidin at baseline to differentiate between response and non-response to iron therapy with oral ferrous fumarateTime frame: Week 14
  2. The discriminative capacity of hepcidin at baseline to differentiate between response and non-response to iron therapy with oral ferric maltolTime frame: Week 14
  3. The discriminative capacity of hepcidin at baseline to differentiate between response and non-response to intravenous iron therapyTime frame: Week 14

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Amsterdam University Medical Center

    Amsterdam, Netherlands · Recruiting

  • University Medical Center Groningen

    Groningen, Netherlands · Recruiting

  • Leiden University Medical Center (LUMC)

    Leiden, Netherlands · Recruiting

  • Maastricht University Medical Center+

    Maastricht, Netherlands · Recruiting

  • Radboud University Medical Center

    Nijmegen, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.